MSMałgorzata Sadowska

Małgorzata Sadowska

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Małgorzata Sadowska has a total of 45 co-authors. Here are the top co-authors by number of shared publications:

  • Tomasz Demkow

    Department of Uro-oncology, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, 5, Roentgen Street, 02-781, Warsaw, Poland

    7 shared publications
  • Paweł Wiechno

    Department of Uro-oncology, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, 5, Roentgen Street, 02-781, Warsaw, Poland

    6 shared publications
  • Jakub Kucharz

    Department of Genitourinary Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland

    4 shared publications
  • Karol Nietupski

    Department of Uro-oncology, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, 5, Roentgen Street, 02-781, Warsaw, Poland

    4 shared publications
  • Wojciech Michalski

    Department of Uro-oncology, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, 5, Roentgen Street, 02-781, Warsaw, Poland

    4 shared publications
  • Grazyna Poniatowska

    Department of Uro-oncology, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, 5, Roentgen Street, 02-781, Warsaw, Poland

    2 shared publications

Latest Publications

  • Contemporary treatment of metastatic renal cell carcinoma

    by Pawel Wiechno, Jakub Kucharz, Malgorzata Sadowska, Wojciech Michalski, Bozena Sikora-Kupis, Joanna Jonska-Gmyrek, Grazyna Poniatowska, Karol Nietupski, Krzysztof Ossolinski, Tomasz Demkow

    Renal cell carcinoma is the 14th most common cancer worldwide. It is a heterogeneous group of histopathological entities, of which the most common is clear cell renal cell carcinoma. Approximately 20–30% of patients present initially with metastatic disease and an additional 20% will progress after radical surgical treatment. Metastatic disease that is non-feasible for surgical treatment remains incurable. Numerous studies have demonstrated that—with the introduction of new drugs—the treatment outcomes of metastatic disease have improved. The development of new therapies as well as the optimization and individualization of procedures allow us to hope for further progress in this area.


  • Testicular teratomas: a growing problem?

    by Wojciech Michalski, Joanna Jonska-Gmyrek, Grazyna Poniatowska, Jakub Kucharz, Pawel Stelmasiak, Karol Nietupski, Malgorzata Sadowska, Tomasz Demkow, Pawel Wiechno

    Testicular teratomas represent a specific entity within the group of germ-cell tumours. They may comprise elements of all three germ layers. In contrast to prepubertal benign teratomas observed in infants and adolescents, postpubertal teratomas originate from the malignant germ-cell precursor. Given the good prognosis and curability of most patients with germ-cell tumour, medical oncologists and urological surgeons must be well acquainted with the principles of teratomas management. Surgery plays the decisive part in teratomas treatment, as these tumours are resistant to radio- and, to some extent, chemotherapy. In this article we concentrate on the management of post-chemotherapy resection of teratomatous masses, with special attention to the phenomenon of ‘growing teratoma syndrome’ and somatic-type transformation of teratomas. To understand the nature of teratomas better, we begin with a glimpse of their biological, molecular and immunohistochemical features. Managing germ-cell tumours, teratomas in particular, in high-volume reference centres is of utmost importance to maintain and increase the survivorship rate in these patients.


  • Open Access

    Clinical significance of androgen secretion disorders in men with a malignancy

    by Pawel J. Wiechno, Grazyna M. Poniatowska, Wojciech Michalski, Jakub Kucharz, Malgorzata Sadowska, Joanna Jonska-Gmyrek, Karol Nietupski, Joanna Rzymowska, Tomasz Demkow

    Cancer and its treatment can lead in men to testosterone deficiency, accompanied by somatic and mental symptoms. Germ cell tumours and their treatment may disturb the pituitary–gonadal axis, hence leading to significant clinical abnormalities. In some prostate cancer patients, castration, temporary or permanent, is a desired therapeutic condition. Yet, it is burdened with various side effects of complex intensity and significance. Last but not least, patients in the terminal stage of a malignancy present with low testosterone concentrations as a part of anorexia–cachexia syndrome. Oncological management of such patients disturbs their homeostasis, androgen metabolism included, which results in numerous complications and worsens their quality of life. In the present paper, we analysed the frequency and sequelae of testosterone deficiency in some clinical scenarios, on the basis of original papers, meta-analyses and reviews available in PubMed. Androgen secretion disorders in male cancer patients depend on a cancer type, stage and methods of treatment. Number of testicular cancer survivors is increasing, and as a consequence, more patients cope with late complications, testosterone deficiency included. Hormone therapy in prostate cancer patients significantly prolongs survival, and then numerous men experience long-term adverse effects of androgen deficiency. Those, in turn, particularly the metabolic syndrome, may contribute to increased mortality. Androgen deficiency is a part of cancer anorexia–cachexia syndrome. The role of androgen deficiency in cancer patients is still under debate, and further studies are urgently needed to establish appropriate clinical guidelines.


  • Open Access

    Dynamics of hormonal disorders following unilateral orchiectomy for a testicular tumor

    by Paweł J. Wiechno, Maria Kowalska, Jakub Kucharz, Małgorzata Sadowska, Wojciech Michalski, Grażyna Poniatowska, Joanna Jońska-Gmyrek, Joanna Rzymkowska, Karol Nietupski, Tomasz Demkow

    Testicular tumors and their treatment interfere with homeostasis, hormonal status included. The aim of the study was to evaluate hormonal disorders of the pituitary–gonadal axis in men treated for testicular tumors. One hundred twenty-eight men treated for a unilateral testicular tumor at our institution were included. The hormonal status was prospectively evaluated in 62 patients before orchiectomy, 120 patients 1 month after orchiectomy and 110 patients at least 1 year after the treatment. The concentrations of human chorionic gonadotropin (hCG), testosterone (T), estradiol, luteinizing hormone (LH), follicle-stimulating hormone (FSH) and prolactin were measured. The clinically significant testosterone deficiency was defined either as testosterone <2.31 ng/mL or testosterone within the range of 2.31–3.46 ng/mL but simultaneous with T/LH ratio ≤1. Changes in hormone levels were significant: LH and FSH rose in the course of observation, and the concentration of hCG, testosterone, estradiol decreased. PRL concentration was the lowest at 1 month after orchiectomy. In multivariate analysis, the risk of the clinically significant testosterone deficiency was 0.2107 (95% CI 0.1206–0.3419) prior to orchiectomy, 0.3894 (95% CI 0.2983–0.4889) 1 month after surgery and 0.4972 (95% CI 0.3951–0.5995) 1 year after the treatment. The estradiol concentration was elevated in 40% of patients with recently diagnosed testicular cancer and that was correlated with a higher risk of testosterone deficiency after the treatment completion. Hormonal disorders of the pituitary–gonadal axis in men treated for testicular tumors are frequent. The malignant tissue triggers paraneoplastic disorders that additionally disturb the hormonal equilibrium.


  • Does pharmacological castration as adjuvant therapy for prostate cancer after radiotherapy affect anxiety and depression levels, cognitive functions and quality of life?

    by Paweł J. Wiechno, Małgorzata Sadowska, Tomasz Kalinowski, Wojciech Michalski, Tomasz Demkow

    Introduction: Adjuvant hormonotherapy for prostate cancer patients after radical radiotherapy has a well‐established value. However, the impact of such treatment on the patients' quality of life remains to be elucidated.Objective: The objective is to assess the impact of adjuvant hormonotherapy with luteinizing hormone‐releasing hormone analogue after radical radiotherapy on anxiety and depression levels, cognitive function, sexual function and quality of life of prostate cancer patients.Material and Methods: Two groups of patients were tested: men treated with adjuvant hormonotherapy (88 patients) and men without hormonotherapy (61 patients). Anxiety, depression and cognitive functions were evaluated. Patients answered questions addressing problems linked to hormonal equilibrium. The patients rated their mental status, physical status, quality of life and quality of their relationship.Results: There were no statistically significant differences between patients on hormonotherapy and without hormonotherapy in the level of anxiety and depression (p = 0.844 and p = 0.954) as well as in cognitive function (p = 0.661). Satisfactory sexual performance was preserved in 9/65 patients (14%) on hormonotherapy and the same was applied to 19/49 patients (39%) without hormonotherapy. The difference was statistically significant (p = 0.003). Hormonotherapy was associated with decreased libido (p = 0.031), hot flushes (p < 0.001) and sweating (p < 0.001). No statistically significant differences were found between the groups in the self‐rated physical and psychological well‐being (p = 0.476 and p = 0.597), quality of life (p = 0.622) and quality of relationship (p = 0.064).Conclusions: Adjuvant hormonotherapy enhances neither anxiety nor depression, does not impair cognitive function but has a negative effect on the patients' sexual function. It does not worsen self‐rated quality of relationship and quality of life. Copyright © 2011 John Wiley & Sons, Ltd.


  • Open Access

    Gene therapy of locally advanced vulvar cancer with psFLT construct

    by Krzysztof Gawrychowski, Maciej Małecki, Grzegorz Szewczyk, Grzegorz Panek, Wacław Śmiertka, Katarzyna Roszkowska-Purska, Mariusz Bidziński, Małgorzata Sadowska, Joanna Surowińska, Monika Dąbrowska, et al.

    Introduction: An interesting strategy in experimental therapy of neoplasms is genetic-based antiangiogenic therapy. The basis for this therapy is the premise that development of new tumour vessels is a direct factor for tumour growth. The psFLT construct is a plasmid expression vector that...

  • The Quality of Life and Hormonal Disturbances in Testicular Cancer Survivors in Cisplatin Era

    by Paweł Wiechno, Tomasz Demkow, Krzysztof Kubiak, Małgorzata Sadowska, Janina Kamińska


  • Open Access

    Increased cancer risk of heterozygotes with NBS1 germline mutations in poland

    by Jan Steffen, Raymonda Varon, Maria Mosor, Galina Maneva, Martin Maurer, Markus Stumm, Dorota Nowakowska, Maryna Rubach, Ewa Kosakowska, Włodzimierz Ruka, et al.

    It has been suggested based on familial data that Nijmegen breakage syndrome (NBS) heterozygotes have an increased risk of malignant tumors. We found 15 carriers of the 657del5 mutation and 8 carriers of the R215W molecular variant of the NBS1 gene among 1,289 consecutive patients from Central Poland with various cancers and only 10 and 4 such carriers, respectively, in 1,620 controls from this region. Most of the 657del5 mutation carriers were found among patients with melanoma (4/105), non‐Hodgkin lymphoma (2/42) and breast cancer (4/224) and of the 234 patients with colorectal carcinoma 3 carried the 657del5 mutation and 3 others the R215W molecular variant. The frequencies of 657del5 mutation carriers among patients with melanoma and non‐Hodgkin lymphoma and of R215W carriers in patients with colorectal cancer were significantly higher than in controls (p < 0.01, < 0.05 and < 0.05 respectively). The pooled frequencies of 657del5 and R215W mutations in all cancer patients were also significantly higher than in controls (p < 0.05). Two carriers of the 657del5 mutation had second primary tumors. Malignant tumors among parents and siblings of 657del5 mutation carriers (14/77) were twice more frequent than in population controls. Three carriers of this mutation (2 probands with melanoma) reported melanoma in relatives. These results suggest strongly that NBS1 heterozygosity may be associated with elevated risk of some cancers. Larger studies are needed to evaluate the impact of the high frequency of germline NBS1 mutations on the cancer burden in the Slav populations.